Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Generating clinical evidence for treatment and prevention options for long COVID

Nature Medicine volume 30, pages 2109–2110 (2024)Cite this article

Subjects

Long COVID is a chronic and debilitating disease affecting more than 36 million people in the European Union (EU)1. Most patients are of working age, creating a high burden on healthcare and social systems2. At present, there are no EU-approved medicines for the treatment or prevention of long COVID.

The long COVID therapeutic field is at a crossroads, with many study designs being proposed and used in ongoing clinical research. However, the lack of a standardized definition and common ICD-10 code for long COVID and the complexity of the pathophysiological mechanisms and clinical syndromes associated with the condition3 pose substantial challenges to the design of clinical trials to evaluate therapeutic and preventive approaches for these conditions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. World Health Organization. https://go.nature.com/3UZjXtm (2023).

  2. Davis, H. E. et al. EClinicalMedicine 38, 101019 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. Nat. Rev. Microbiol. 21, 133–146 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. European Medicines Agency. https://go.nature.com/3wpJzXc (2023).

  5. European Medicines Agency. EMA/340269/2023; https://go.nature.com/44GYMQf (2023).

  6. Klein, J. et al. Nature 623, 139–148 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. & Diaz, J. V. Lancet Infect. Dis. 22, e102–e107 (2022).

    Article  CAS  PubMed  Google Scholar 

  8. Centers for Disease Control and Prevention (CDC). https://go.nature.com/3wnOUhL (2023).

  9. National Institute for Health and Care Excellence (NICE). https://www.nice.org.uk/guidance/ng188/ (2022).

  10. Frere, J. J. et al. Sci. Transl. 14, eabq3059 (2022).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. European Medicines Agency, Amsterdam, The Netherlands

    Stephanie Buchholz, Eugenia Di Meco & Marco Cavaleri

  2. Federal Institute for Drugs and Medical Devices, Bonn, Germany

    Stephanie Buchholz

  3. EMA Emergency Task Force, Amsterdam, The Netherlands

    Eugenia Di Meco, Ewa Z. Bałkowiec-Iskra, Bruno Sepodes & Marco Cavaleri

  4. Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

    Ewa Z. Bałkowiec-Iskra

  5. The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warsaw, Poland

    Ewa Z. Bałkowiec-Iskra

  6. EMA Committee for Medicinal Products for Human Use, Amsterdam, The Netherlands

    Ewa Z. Bałkowiec-Iskra & Bruno Sepodes

  7. Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal

    Bruno Sepodes

Authors
  1. Stephanie Buchholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugenia Di Meco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ewa Z. Bałkowiec-Iskra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruno Sepodes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marco Cavaleri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Cavaleri.

Ethics declarations

Competing interests

The authors declare no competing interests. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organizations with which the author(s) is/are employed/affiliated.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Buchholz, S., Di Meco, E., Bałkowiec-Iskra, E.Z. et al. Generating clinical evidence for treatment and prevention options for long COVID. Nat Med 30, 2109–2110 (2024). https://doi.org/10.1038/s41591-024-03031-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-024-03031-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research